drugset
drugset / Trial / NCT03216096

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

NCT03216096 ↗

Phase 1 Completed 20 enrolled Santen Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess safety and efficacy of DE-089 ophthalmic solution in patients with dry eye disease in Taiwan.

Timeline

Start
2017-09-08
Primary completion
2018-02-01
Completion
2018-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Diquafosol tetrasodium Oligonucleotide (other) 3 % Other

Indications

dry eye syndrome